Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer

被引:14
作者
Forsythe, Anna [1 ]
Chandiwana, David [2 ]
Barth, Janina [3 ]
Thabane, Marroon [4 ]
Baeck, Johan [2 ]
Tremblay, Gabriel [1 ]
机构
[1] Purple Squirrel Econ, 4 Lexington Ave,Suite 15K, New York, NY 10010 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Pharma GmbH, Nurnberg, Germany
[4] Novartis Pharmaceut Inc, Dorval, PQ, Canada
关键词
breast cancer; overall survival; progression-free survival; time to progression; correlation analysis; surrogate endpoint;
D O I
10.2147/BCTT.S162841
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Several recent randomized controlled trials (RCTs) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) have demonstrated significant improvements in progression-free survival (PFS); however, few have reported improvement in overall survival (OS). The surrogacy of PFS or time to progression (TTP) for OS has not been formally investigated in HR+, HER2-MBC. Methods: A systematic literature review of RCTs in HR+, HER2-MBC was conducted to identify studies that reported both median PFS/TTP and OS. The correlation between PFS/TTP and OS was evaluated using Pearson's product-moment correlation and Spearman's rank correlation. Subgroup analyses were performed to explore possible reasons for heterogeneity. Errors-in-variables weighted least squares regression (LSR) was used to model incremental OS months as a function of incremental PFS/TTP months. An exploratory analysis investigated the impact of three covariates (chemotherapy vs hormonal/targeted therapy, PFS vs TTP, and first-line therapy vs second-line therapy or greater) on OS prediction. The lower 95% prediction band was used to determine the minimum incremental PFS/TTP months required to predict OS benefit (surrogate threshold effect [STE]). Results: Forty studies were identified. There was a statistically significant correlation between median PFS/TTP and OS (Pearson = 0.741, P= 0.000; Spearman = 0.650, P= 0.000). These results proved consistent for chemotherapy and hormonal/targeted therapy. Univariate LSR analysis yielded an R-2 of 0.354 with 1 incremental PFS/TTP month corresponding to 1.13 incremental OS months. Controlling the type of treatment (chemotherapy vs hormonal/targeted therapy), line of therapy (first vs subsequent), and progression measure (PFS vs TTP) led to an improved R-2 of 0.569 with 1 PFS/TTP month corresponding to 0.78 OS months. The STE for OS benefit was 5-6 months of incremental PFS/TTP. Conclusion: We demonstrated a significant association between PFS/TTP and OS, which may justify the use of PFS/TTP as a surrogate for OS benefit in HR+, HER2-MBC.
引用
收藏
页码:69 / 78
页数:10
相关论文
共 15 条
[1]  
Burzykowski T., 2005, EVALUATION SURROGATE
[2]   Progression-free survival is a surrogate for survival in advanced colorectal cancer [J].
Buyse, Marc ;
Burzykowski, Tomasz ;
Carroll, Kevin ;
Michiels, Stefan ;
Sargent, Daniel J. ;
Miller, Langdon L. ;
Elfring, Gary L. ;
Pignon, Jean-Pierre ;
Piedbois, Pascal .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5218-5224
[3]   US Food and Drug Administration Approval Overview in Metastatic Breast Cancer [J].
Cortazar, Patricia ;
Justice, Robert ;
Johnson, John ;
Sridhara, Rajeshwari ;
Keegan, Patricia ;
Pazdur, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1705-1711
[4]  
Davis S., 2012, REV STUDIES EXAMININ
[5]   Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer [J].
Di Leo, A ;
Bleiberg, H ;
Buyse, M .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :2045-2047
[6]   Overall Survival: Still the Gold Standard Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials [J].
Driscoll, James J. ;
Rixe, Oliver .
CANCER JOURNAL, 2009, 15 (05) :401-405
[7]  
Forsythe A, 2018, CANC MANAG IN PRESS
[8]   End points and United States food and drug administration approval of oncology drugs [J].
Johnson, JR ;
Williams, G ;
Pazdur, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1404-1411
[9]   Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents [J].
Saad, E. D. ;
Buyse, M. .
ANNALS OF ONCOLOGY, 2016, 27 (03) :373-378
[10]   Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials [J].
Saad, Everardo D. ;
Katz, Artur ;
Buyse, Marc .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1958-1962